Neurocrine Biosciences
NBIX
#1480
Rank
$15.14 B
Marketcap
$150.59
Share price
-1.09%
Change (1 day)
25.04%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): $6.71

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $6.71. In 2025 the company made an earnings per share (EPS) of $4.82 an increase over its 2024 EPS that were of $3.38.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)$6.7139.21%
2025$4.8242.6%
2024$3.3833.07%
2023$2.5457.76%
2022$1.6169.47%
2021$0.95-78.21%
2020$4.36990%
2019$0.4081.82%
2018$0.22-113.5%
2017-$1.630.62%
2016-$1.6257.28%
2015-$1.0325.61%
2014-$0.8218.84%
2013-$0.69-1085.71%
2012$0.07000

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
$1.31-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
$2.06-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
$28.23 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
$0.92-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-$2.03-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
$3.50-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-$29.90-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
$1.90-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK